Table 4.
Effect of the tested drugs on the liver and kidney functions in alloxan-induced diabetic rats after 4 weeks
| Biochemicals | ||||
|---|---|---|---|---|
| Group | ALP(IU/L) | AST(IU/L) | Urea (mmol/L) | Creatinine (mmol/L) |
| Normal control group | 60.85 ± 8.77 | 25.04 ± 4.96 | 43.38 ± 4.77 | 0.46 ± 0.07 |
| Diabetic control group | 89.05 ± 10.44* | 45.86 ± 7.57* | 75.81 ± 18.85* | 1.89 ± 0.19* |
| Diabetic group treated with Bromocriptine | 68.83 ± 7.27# | 34.18 ± 5.78# | 60.41 ± 6.22# | 1.04 ± 0.26# |
| Diabetic group treated with Cabergoline | 73.27 ± 7.93# | 21.37 ± 10.05# | 52.09 ± 2.23# | 0.79 ± 0.11# |
| Diabetic group treated with Sarpogrelate | 82.16 ± 23.83 | 41.47 ± 10.02 | 69.41 ± 7.65 | 1.68 ± 0.25 |
| Diabetic group treated with Bromocriptine + sarpogrelate | 64.8 ± 7.21# | 31.03 ± 6.44# | 44.4 ± 8.23# | 1.26 ± 0.25# |
| Diabetic group treated with cabergoline + sarpogrelate | 73.44 ± 6.68# | 33.79 ± 11.18# | 51.16 ± 10.43# | 1.33 ± 0.21# |
Values shown are means ± SEM; n = 6 rats per group. * P < 0.05, significantly different from the normal control group; # P < 0.05, significantly different from the diabetic control group